3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Wilms Tumor
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Hepatoblastoma
1
Carcinoma, Renal Cell
1
Interventions
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Carboplatin
4
Biopsy
4
tazemetostat
3
Mesna
3
Melphalan
3
Ifosfamide
3
Granulocyte Colony-Stimulating Factor
3
Etoposide
3
Cyclophosphamide
3
Busulfan
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
fludarabine
2
etoposide phosphate
2
erdafitinib
2
ensartinib
2
Vemurafenib
2
Thiotepa
2
Temozolomide
2
Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdoid Tumor
×
pegylated granulocyte colony-stimulating factor
×
Genitourinary
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled